DPX 0907

Drug Profile

DPX 0907

Alternative Names: DPX-0907

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Immunovaccine
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 08 Nov 2016 Immunovaccine terminates its licence for DPX 0907 with Immunotope
  • 08 Nov 2016 Discontinued - Phase-I for Breast cancer, Ovarian cancer and Prostate cancer in USA (SC)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top